OTC Monograph Route More Onerous Than NDA Process – ONP Official

Companies seeking to market OTC products should consider a new drug application versus the monograph route when both are options because NDAs will yield a "faster turnaround," said Office of Nonprescription Products Associate Director Susan Johnson